Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O15194

UPID:
CTDSL_HUMAN

ALTERNATIVE NAMES:
Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 3; NIF-like protein; Nuclear LIM interactor-interacting factor 1; Protein YA22; RBSP3; Small C-terminal domain phosphatase 3

ALTERNATIVE UPACC:
O15194; Q3ZTU0; Q70KI4; Q7Z5Q2

BACKGROUND:
CTD small phosphatase-like protein, identified by its alternative names such as RBSP3 and Protein YA22, is recruited by REST to silence neuronal genes in non-neuronal cells. It preferentially targets the dephosphorylation of Ser-5 within POLR2A's CTD, negatively regulating RNA polymerase II transcription. This protein's unique function underscores its pivotal role in maintaining cellular identity and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of CTD small phosphatase-like protein offers a pathway to innovative therapeutic approaches. By elucidating its role in transcriptional regulation, researchers can identify novel strategies to correct gene expression imbalances in disease states, paving the way for targeted therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.